Company intelligence / Profile preview

DiagnosTear

Tel Aviv, Tel Aviv District, Israelbio-light.co.il ↗

Ownership: Private
Development stage: Other

Overview

DiagnosTear’s TeaRx™ platform has CE-IVD approval in Europe for the diagnosis and monitoring of Dry Eye Syndrome. The company has completed four clinical studies in the US and Israel demonstrating efficacy in diagnosing DES. Ongoing large-scale clinical trials are underway with leading academic partners to further validate and expand its diagnostic capabilities to other front-of-eye diseases such as red eye conditions.

Therapeutic areas: OphthalmologyImmunologyInfectious Diseases
Modalities: DeviceDiagnostic assayMicrofluidic technology
Industry: Protein Biomarker Diagnostics

Partnerships

Lexitas Pharma Services Inc.LV Prasad Eye InstituteGlobal pharmaceutical company (unnamed)

Beyond the preview

Go deeper on DiagnosTear.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiagnosTear.

Explore the full profile